PGIM India Healthcare Fund vs WhiteOak Capital Pharma and Healthcare Fund
Direct Plan, Growth option · Data as on 30-10-2026
PGIM India Healthcare Fund is a Thematic fund and WhiteOak Capital Pharma and Healthcare Fund is a Sectoral fund. In the year to 30-10-2026, PGIM India Healthcare Fund (Direct) returned 18.1% and WhiteOak Capital Pharma and Healthcare Fund (Direct) returned 19.5%. PGIM India Healthcare Fund charges 0.98% a year and WhiteOak Capital Pharma and Healthcare Fund 1.07% (Direct plans). Their portfolios overlap 51.4%: they hold 22 of the same securities.
PGIM India Healthcare Fund
Thematic
- 1 year return
- 18.1%
- Expense ratio
- 0.98%
- NAV
- ₹12.10
WhiteOak Capital Pharma and Healthcare Fund
Sectoral
- 1 year return
- 19.5%
- Expense ratio
- 1.07%
- NAV
- ₹17.44
Which is better, PGIM India Healthcare or WhiteOak Capital Pharma and Healthcare? Key differences
It depends on what you want from the fund. These are the differences in numbers, from the data on this page.
- WhiteOak Capital Pharma and Healthcare returned more over 1 year: 19.5% against 18.1%.
- PGIM India Healthcare costs less: 0.98% a year against 1.07% (Direct plans).
- PGIM India Healthcare fell less in its worst fall since 11-12-2024: −14.4% against −15.4%.
- WhiteOak Capital Pharma and Healthcare is the larger fund: ₹927 Cr against ₹130 Cr.
- Their portfolios overlap 51.4%: 22 of the same holdings.
Past returns do not promise future returns. This page is information, not investment advice.
Key facts
From each fund's scheme summary document and AMFI
| Fact | PGIM India Healthcare Fund | WhiteOak Capital Pharma and Healthcare Fund |
|---|---|---|
| Fund house | PGIM India Mutual Fund | WhiteOak Capital Mutual Fund |
| Category | Thematic | Sectoral |
| AUM | ₹130 Cr (30-09-2026) | ₹927 Cr (30-09-2026) |
| NAV | ₹12.10 (Direct) | ₹17.44 (Direct) |
| Expense ratio (Direct) | 0.98% | 1.07% |
| Expense ratio (Regular) | 2.65% | 2.75% |
| Riskometer | Very High | Very High |
| Benchmark | BSE Healthcare TRI | BSE Healthcare TRI |
| Launch date | 06-12-2024 | 06-02-2024 |
| Minimum investment | ₹5,000 | ₹500 |
| Lock in | None | None |
| Fund managers | Anandha Padmanabhan Anjeneyan, Utsav Mehta, Vivek Sharma, and Mr. Puneet Pal | Ramesh Mantri, Piyush Baranwal, Dheeresh Pathak, Ashish Agrawal, Trupti Agrawal |
| Exit load | Exit load of 0.50%, if redeemed within 90 days. | Nil |
PGIM India Healthcare vs WhiteOak Capital Pharma and Healthcare: Returns Comparison
Returns as on 30-10-2026. Up to one year they are absolute returns. Longer periods are a rate per year.
| Fund | 1M | 3M | 6M | 1Y | 3Y | 5Y | 10Y |
|---|---|---|---|---|---|---|---|
| PGIM India Healthcare Fund (Direct) | −1.22% | −1.14% | +15.90% | +18.05% | -- | -- | -- |
| WhiteOak Capital Pharma and Healthcare Fund (Direct) | +0.92% | +1.33% | +17.99% | +19.53% | -- | -- | -- |
| Thematic average | −2.09% | −4.52% | +0.86% | −1.22% | -- | -- | -- |
| Sectoral average | −1.70% | −4.49% | +2.30% | −0.58% | -- | -- | -- |
Category average: the average of the 235 Thematic funds and the 20 Sectoral funds, same plan type.
PGIM India Healthcare vs WhiteOak Capital Pharma and Healthcare: Year-wise Returns
| Year | PGIM IndiaPGIM India Healthcare | WhiteOak Capital Pharma andWhiteOak Capital Pharma and Healthcare | BSE Healthcare TRI |
|---|---|---|---|
| 2026to date | +20.76% | +22.83% | +15.08% |
| 2025 | −0.99% | +1.84% | −2.72% |
PGIM India Healthcare vs WhiteOak Capital Pharma and Healthcare: Rolling Returns
Every holding period of both funds, against BSE Healthcare TRI, the benchmark of both
Rolling returns
Every 1-year holding period, 217 of them, one for each trading day from 11-12-2025 to 30-10-2026: the yearly return (CAGR) of each, plotted on the day it ended. One lucky or unlucky start day cannot flatter or hide a fund.
PGIM India Healthcare Fund (Direct)
WhiteOak Capital Pharma and Healthcare Fund (Direct)
BSE Healthcare TRI
to
Jan 2026Mar 2025
to
Mar 2026Apr 2025
to
Apr 2026Jun 2025
to
Jun 2026Aug 2025
to
Aug 2026Oct 2025
to
Oct 2026
How the periods spread
| Fund | Below 0% | 0-5% | 5-10% | 10-15% | 15-20% | 20-25% | Above 25% | Mean | Median | Lowest | Highest | Beat benchmark |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PGIM India Healthcare | 9.2 | 13.8 | 11.1 | 21.2 | 22.1 | 12.0 | 10.6 | 13.1% | 13.8% | −3.0% | 29.3% | 97% |
| WhiteOak Capital Pharma and Healthcare | 0.0 | 12.0 | 13.8 | 14.7 | 30.9 | 25.3 | 3.2 | 15.1% | 17.1% | 0.6% | 26.6% | 100% |
| BSE Healthcare TRI | 13.8 | 14.3 | 20.7 | 36.4 | 14.7 | 0.0 | 0.0 | 8.7% | 10.2% | −3.7% | 19.5% | -- |
The table shows the % of periods in each return band; a darker cell holds more of them. Lumpsum: the yearly rate (CAGR) from a period's first NAV to its last. SIP: the XIRR of the monthly instalments. The benchmark is BSE Healthcare TRI, over the same periods. "Beat benchmark" counts the periods in which the fund did better. Every fund is measured over the days all of them have, from 11-12-2024. Past returns do not promise future returns.
PGIM India Healthcare vs WhiteOak Capital Pharma and Healthcare: SIP and Lumpsum Returns
What the same monthly or one-time investment would be worth in each fund today, from their own NAV history
Growth of an investment
₹10,000 on the first trading day of every month, from 11-12-2024 to 30-10-2026: 23 instalments, ₹2,30,000 in all.
| Investment | Invested | Value now | Gain | Return a year |
|---|---|---|---|---|
| PGIM India HealthcarePGIM India Healthcare Fund (Direct) | ₹2,30,000 | ₹2,72,424 | ₹42,424 | 18.1% |
| WhiteOak Capital Pharma and HealthcareWhiteOak Capital Pharma and Healthcare Fund (Direct) | ₹2,30,000 | ₹2,80,027 | ₹50,027 | 21.2% |
PGIM India HealthcarePGIM India Healthcare Fund (Direct)
WhiteOak Capital Pharma and HealthcareWhiteOak Capital Pharma and Healthcare Fund (Direct)
Amount invested
From each plan's published NAV (Growth option), over the same days. Return a year: XIRR for a SIP, CAGR for a lumpsum, shown for a year or more. It does not include exit load, stamp duty or tax. Past returns do not promise future returns.
PGIM India Healthcare vs WhiteOak Capital Pharma and Healthcare: Risk and Drawdowns
How much each fund swings, and the worst fall over the same days
Risk and return
| Measure | PGIM India Healthcare Fund (Direct) | WhiteOak Capital Pharma and Healthcare Fund (Direct) |
|---|---|---|
| Return (CAGR) | +18.05% | +19.53% |
| Standard deviation | 12.68% | 13.75% |
| Sharpe ratio | 1.01 | 1.04 |
| Sortino ratio | 1.50 | 1.57 |
| Maximum drawdown | −10.0% (23-10-2026) | −9.8% (23-10-2026) |
| Beta | 0.87 | 0.97 |
| Alpha | +6.61% | +7.36% |
From daily NAVs, 30-10-2025 to 30-10-2026. Standard deviation: how much the daily value swings, scaled to a year. Sharpe: return above the risk-free rate (NSE's overnight rate index) per unit of swing. Sortino: the same, counting only the falls. Beta and alpha compare each fund with its own benchmark's TRI.
| Measure | PGIM India Healthcare Fund (Direct) | WhiteOak Capital Pharma and Healthcare Fund (Direct) |
|---|---|---|
| Return (CAGR) | +10.77% | +22.30% |
| Standard deviation | 13.07% | 14.35% |
| Sharpe ratio | 0.40 | 1.14 |
| Sortino ratio | 0.54 | 1.62 |
| Maximum drawdown | −14.4% (28-02-2025) | −15.4% (28-02-2025) |
| Beta | 0.84 | 0.97 |
| Alpha | +3.79% | +7.59% |
From daily NAVs, 11-12-2024 to 30-10-2026. Standard deviation: how much the daily value swings, scaled to a year. Sharpe: return above the risk-free rate (NSE's overnight rate index) per unit of swing. Sortino: the same, counting only the falls. Beta and alpha compare each fund with its own benchmark's TRI.
Drawdowns
How far below its previous high each one was on every day: the falls an investor had to sit through. 0% means it was at a new high.
PGIM India Healthcare Fund (Direct)
WhiteOak Capital Pharma and Healthcare Fund (Direct)
BSE Healthcare TRI
| Fund | Worst fall | High before it | Bottom | Back at the high | Time to climb back | Below its high today |
|---|---|---|---|---|---|---|
| PGIM India Healthcare Fund (Direct) | −14.4% | 07-01-2025 | 28-02-2025 | 15-07-2025 | 5 months | −5.1% |
| WhiteOak Capital Pharma and Healthcare Fund (Direct) | −15.4% | 02-01-2025 | 28-02-2025 | 14-07-2025 | 4 months | −3.0% |
| BSE Healthcare TRI | −16.2% | 02-01-2025 | 28-02-2025 | 29-07-2025 | 5 months | −3.8% |
From daily values since 11-12-2024, the first day every fund has.
Rolling standard deviation
Whether the swings have grown or calmed over time: the standard deviation of daily changes over every 1-year window, scaled to a year, plotted on the window's last day. Higher means a bumpier ride.
PGIM India Healthcare Fund (Direct)
WhiteOak Capital Pharma and Healthcare Fund (Direct)
BSE Healthcare TRI
Against BSE Healthcare TRI
| Fund | Up capture | Down capture | Tracking error |
|---|---|---|---|
| PGIM India Healthcare Fund (Direct) | 110% | 95% | 3.86% |
| WhiteOak Capital Pharma and Healthcare Fund (Direct) | 116% | 92% | 2.71% |
From month-end values since 11-12-2024. Up capture: a fund's average month when the benchmark rose, as % of the benchmark's; above 100% it gained more. Down capture: the same for months the benchmark fell; below 100% it fell less. Tracking error: how far the monthly returns strayed from the benchmark's, a year; an index fund aims near 0.
PGIM India Healthcare vs WhiteOak Capital Pharma and Healthcare: Portfolio Overlap
From each fund's latest monthly portfolio: PGIM India Healthcare Fund, September 2026; WhiteOak Capital Pharma and Healthcare Fund, September 2026
Holdings in common
- Overlap
- 51.4%
- Held by both
- 22
- Only in PGIM India Healthcare
- 9
- Only in WhiteOak Capital Pharma and Healthcare
- 37
| Security | % of PGIM India Healthcare | % of WhiteOak Capital Pharma and Healthcare |
|---|---|---|
| Divi's Laboratories Ltd. | 10.36% | 8.36% |
| Sun Pharmaceutical Industries Ltd. | 10.25% | 7.11% |
| Torrent Pharmaceuticals Ltd. | 8.49% | 6.26% |
| Neuland Laboratories Ltd. | 2.91% | 2.60% |
| Sai Life Sciences Ltd | 2.54% | 3.28% |
| Dr. Lal Path Labs Ltd. | 4.33% | 2.35% |
| Zydus Lifesciences Ltd. | 2.04% | 2.81% |
| Cipla Ltd. | 2.04% | 3.68% |
| Ajanta Pharma Ltd. | 4.96% | 2.01% |
| IPCA Laboratories Ltd. | 1.92% | 2.88% |
| Krishna Inst of Medical Sciences Ltd. | 2.99% | 1.85% |
| Max Healthcare Institute Ltd. | 4.71% | 1.84% |
| Anthem Biosciences Ltd. | 1.81% | 1.57% |
| Global Health Ltd. | 1.52% | 1.82% |
| Navin Fluorine International Ltd. | 3.24% | 1.41% |
| Fortis Healthcare Ltd. | 1.46% | 1.36% |
| Mankind Pharma Ltd. | 4.04% | 1.20% |
| Gland Pharma Ltd. | 1.50% | 0.93% |
| Molbio Diagnostics Ltd. | 0.80% | 1.15% |
| Jupiter Life Line Hospitals Ltd. | 1.46% | 0.73% |
| Manipal Health Enterprises Ltd. | 3.68% | 0.52% |
| Orchid Pharma Ltd. | 0.79% | 0.41% |
Overlap: for each holding both funds own, the smaller of its two weights, added up. 51.4% means 51.4% of each fund's money sits in positions the other also holds. Matched by ISIN. Cash and hedged positions are left out.
Largest holdings only in PGIM India Healthcare Fund
| Security | % of fund |
|---|---|
| Abbott India Ltd. | 3.12% |
| Rubicon Research Ltd. | 2.99% |
| Aster DM Quality Care Ltd. | 2.56% |
| ICICI Lombard General Insurance Co. Ltd. | 2.10% |
| Lupin Ltd. | 1.93% |
Largest holdings only in WhiteOak Capital Pharma and Healthcare Fund
| Security | % of fund |
|---|---|
| Laurus Labs Limited | 3.91% |
| Apollo Hospitals Enterprise Limited | 3.75% |
| Corona Remedies Limited | 2.34% |
| Thyrocare Technologies Limited | 2.27% |
| Aurobindo Pharma Limited | 2.09% |
Asset and sector split
Share of each fund, from its latest monthly portfolio
Asset allocation
| Asset | PGIM India Healthcare | WhiteOak Capital Pharma and Healthcare |
|---|---|---|
| Equity | 94.9% | 90.7% |
| Debt | 0.0% | 3.1% |
| Cash and others | 5.1% | 6.1% |
Market cap of stocks
| Market cap | PGIM India Healthcare | WhiteOak Capital Pharma and Healthcare |
|---|---|---|
| Large Cap | 31.1% | 29.2% |
| Mid Cap | 31.6% | 21.7% |
| Small Cap | 25.1% | 37.5% |
| Not on AMFI's list | 7.0% | 2.4% |
Share of the whole fund. Groups follow AMFI's latest list: Large Cap is the 100 largest companies, Mid Cap the next 150, Small Cap the rest.
Largest sectors
| Sector | PGIM India Healthcare | WhiteOak Capital Pharma and Healthcare |
|---|---|---|
| Pharmaceuticals & Biotechnology | 62.8% | 61.2% |
| Healthcare Services | 24.6% | 23.0% |
| Chemicals & Petrochemicals | 3.2% | 3.3% |
| Insurance | 2.1% | 0.0% |
| Consumer Durables | 0.0% | 1.8% |
| Healthcare Equipment & Supplies | 0.8% | 1.4% |
| Retailing | 1.0% | 0.0% |
The six largest sectors of each fund's stocks, % of the fund.
PGIM India Healthcare vs WhiteOak Capital Pharma and Healthcare: Expense Ratio
What each plan charges a year, from AMFI's expense ratio file
| Charge | PGIM India Healthcare Fund | WhiteOak Capital Pharma and Healthcare Fund |
|---|---|---|
| Total expense ratio (Direct) | 0.98% | 1.07% |
| Base expense ratio (Direct) | 0.68% | 0.54% |
| Total expense ratio (Regular) | 2.65% | 2.75% |
| Base expense ratio (Regular) | 2.10% | 1.96% |
The expense ratio comes out of the fund's assets every day, so every return on this page is already after it. Base expense ratio: the fund house's own fee. The total adds brokerage, transaction costs, and levies with GST.
More comparisons
Each fund against the others of its category
Compare PGIM India Healthcare with
Compare WhiteOak Capital Pharma and Healthcare with
- WhiteOak Capital Pharma and Healthcare vs DSP Healthcare
- WhiteOak Capital Pharma and Healthcare vs Nippon India Pharma
- WhiteOak Capital Pharma and Healthcare vs Bandhan Transportation and Logistics
- WhiteOak Capital Pharma and Healthcare vs Nippon India Power & Infra
- WhiteOak Capital Pharma and Healthcare vs Invesco India Financial Services
PGIM India Healthcare Fund vs WhiteOak Capital Pharma and Healthcare Fund: Frequently Asked Questions
What is the difference between PGIM India Healthcare Fund and WhiteOak Capital Pharma and Healthcare Fund?
PGIM India Healthcare Fund is a Thematic fund, WhiteOak Capital Pharma and Healthcare Fund is a Sectoral fund, run by PGIM India Mutual Fund and WhiteOak Capital Mutual Fund. Their portfolios overlap 51.4%. PGIM India Healthcare Fund charges 0.98% a year and WhiteOak Capital Pharma and Healthcare Fund 1.07%.
Which has given higher returns, PGIM India Healthcare Fund or WhiteOak Capital Pharma and Healthcare Fund?
Over 1 year: PGIM India Healthcare Fund +18.05%, WhiteOak Capital Pharma and Healthcare Fund +19.53%. As on 30-10-2026. Past returns do not promise future returns.
Which has the lower expense ratio, PGIM India Healthcare Fund or WhiteOak Capital Pharma and Healthcare Fund?
PGIM India Healthcare Fund charges less: 0.98% a year against 1.07%. These are the Direct plans' total expense ratios reported to AMFI.
How much do PGIM India Healthcare Fund and WhiteOak Capital Pharma and Healthcare Fund overlap?
51.4%. They hold 22 of the same securities, the largest shared ones being DIVISLAB, SUNPHARMA, TORNTPHARM. From each fund's latest monthly portfolio.
Which is riskier, PGIM India Healthcare Fund or WhiteOak Capital Pharma and Healthcare Fund?
On SEBI's riskometer, PGIM India Healthcare Fund is rated Very High and WhiteOak Capital Pharma and Healthcare Fund Very High. Over 1 years, the standard deviation of daily returns was 12.68% and 13.75% a year.
Can I invest in both PGIM India Healthcare Fund and WhiteOak Capital Pharma and Healthcare Fund?
Yes. 51.4% of each fund's money sits in the same holdings, so a large part of the two investments would move together.
Who manages PGIM India Healthcare Fund and WhiteOak Capital Pharma and Healthcare Fund?
PGIM India Healthcare Fund: Anandha Padmanabhan Anjeneyan, Utsav Mehta, Vivek Sharma, and Mr. Puneet Pal. WhiteOak Capital Pharma and Healthcare Fund: Ramesh Mantri, Piyush Baranwal, Dheeresh Pathak, Ashish Agrawal, Trupti Agrawal.
Sources: NAV and expense ratio from AMFI. Holdings from each fund house's monthly portfolio statement. Fund facts from each scheme summary document.
This page is information, not investment advice. Mutual fund investments are subject to market risks; read all scheme related documents carefully. Past returns do not promise future returns. Figures come from AMFI, NSE, BSE and each fund house's own documents.